Home/IXALTIS/Elisabeth Svanberg
ES

Elisabeth Svanberg

Chief Development Officer

IXALTIS

IXALTIS Pipeline

DrugIndicationPhase
Litoxetine (IXA-001)Undisclosed Urogenital Disorder (likely female)Phase 2
IXA-002Undisclosed Genitourinary DisorderUndisclosed
IXA-003Undisclosed Genitourinary DisorderUndisclosed